|
Name |
7-epi-Brefeldin A
|
Molecular Formula | C16H24O4 | |
IUPAC Name* |
(1R,2R,3E,7S,11E,13S,15R)-2,15-dihydroxy-7-methyl-6-oxabicyclo[11.3.0]hexadeca-3,11-dien-5-one
|
|
SMILES |
C[C@H]1CCC/C=C/[C@@H]2C[C@H](C[C@H]2[C@@H](/C=C/C(=O)O1)O)O
|
|
InChI |
InChI=1S/C16H24O4/c1-11-5-3-2-4-6-12-9-13(17)10-14(12)15(18)7-8-16(19)20-11/h4,6-8,11-15,17-18H,2-3,5,9-10H2,1H3/b6-4+,8-7+/t11-,12+,13+,14+,15+/m0/s1
|
|
InChIKey |
KQNZDYYTLMIZCT-MBKTUJMASA-N
|
|
Synonyms |
7-epi-Brefeldin; 7-epi-Brefeldin A; S66RHK02RP; NSC-372200; (1R,2E,6S,10E,11aS,13R,14aR)-1,6,7,8,9,11a,12,13,14,14a-Decahydro-1,13-dihydroxy-6-methyl-4H-cyclopent(f)oxacyclotridecin-4-one; 4H-Cyclopent(f)oxacyclotridecin-4-one, 1,6,7,8,9,11a,12,13,14,14a-decahydro-1,13-dihydroxy-6-methyl-, (1R,2E,6S,10E,11aS,13R,14aR)-; 83710-00-3; UNII-S66RHK02RP
|
|
CAS | 83710-00-3 | |
PubChem CID | 12302047 | |
ChEMBL ID | NA |
Chemical Classification: |
|
|
---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
---|---|---|---|---|---|---|---|---|
Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
Molecular Weight: | 280.36 | ALogp: | 2.0 |
HBD: | 2 | HBA: | 4 |
Rotatable Bonds: | 0 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 66.8 | Aromatic Rings: | 2 |
Heavy Atoms: | 20 | QED Weighted: | 0.529 |
Caco-2 Permeability: | -4.685 | MDCK Permeability: | 0.00014190 |
Pgp-inhibitor: | 0.38 | Pgp-substrate: | 0.537 |
Human Intestinal Absorption (HIA): | 0.028 | 20% Bioavailability (F20%): | 0.056 |
30% Bioavailability (F30%): | 0.963 |
Blood-Brain-Barrier Penetration (BBB): | 0.982 | Plasma Protein Binding (PPB): | 78.34% |
Volume Distribution (VD): | 0.431 | Fu: | 13.18% |
CYP1A2-inhibitor: | 0.028 | CYP1A2-substrate: | 0.108 |
CYP2C19-inhibitor: | 0.035 | CYP2C19-substrate: | 0.248 |
CYP2C9-inhibitor: | 0.047 | CYP2C9-substrate: | 0.875 |
CYP2D6-inhibitor: | 0.011 | CYP2D6-substrate: | 0.446 |
CYP3A4-inhibitor: | 0.491 | CYP3A4-substrate: | 0.239 |
Clearance (CL): | 7.84 | Half-life (T1/2): | 0.878 |
hERG Blockers: | 0.03 | Human Hepatotoxicity (H-HT): | 0.899 |
Drug-inuced Liver Injury (DILI): | 0.429 | AMES Toxicity: | 0.023 |
Rat Oral Acute Toxicity: | 0.831 | Maximum Recommended Daily Dose: | 0.962 |
Skin Sensitization: | 0.833 | Carcinogencity: | 0.879 |
Eye Corrosion: | 0.515 | Eye Irritation: | 0.476 |
Respiratory Toxicity: | 0.323 |
Similar NPs | Similar Drugs | ||||||
---|---|---|---|---|---|---|---|
NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
ENC003784 | 1.000 | D02FEM | 0.248 | ||||
ENC005098 | 1.000 | D0Z1FX | 0.237 | ||||
ENC003460 | 1.000 | D08PIQ | 0.229 | ||||
ENC004599 | 0.697 | D06WTZ | 0.225 | ||||
ENC004602 | 0.697 | D0H0ND | 0.221 | ||||
ENC004603 | 0.676 | D0WE3O | 0.221 | ||||
ENC001860 | 0.672 | D0CZ1Q | 0.217 | ||||
ENC001867 | 0.627 | D0V9DZ | 0.217 | ||||
ENC003403 | 0.627 | D0D2TN | 0.217 | ||||
ENC005407 | 0.559 | D03IKT | 0.213 |